The FDA has approved Rayner’s Ridley Innovation Centre, a $40 million purpose-built R&D, training and production facility in Worthing, UK, according to a company news release. This state-of-the-art, dedicated IOL production center has the capability of manufacturing 3 million IOLs each year, more than tripling Rayner’s previous production capacity. In addition, the new Enterprise Resource Planning (ERP) quality system enables the tracing of every lens from source materials to a patient’s eye.
The new center, which opened in 2017, was enables best-in-class training, education, and research. Featuring a wet lab, library, training facilities, as well as a museum on the history of the world’s first IOL, the Rayner-Ridley lens, the center is focused on engaging and partnering surgeons and academics in new product development. Testament to this culture is an aggressive product pipeline targeting 11 new EU registered products, 5 of which have been approved thus far, transforming Rayner into one of the leading manufacturers of IOLs.
Rayner says the FDA approval of the Ridley Innovation Center is key to registering more of these products in the US market.
“Following up on the recent US launch of the »600C Aspheric lens, FDA approval of The Ridley Innovation Centre marks another exciting step in Rayner’s ambitious growth strategy,” Tim Clover, CEO of Rayner, said in the company news release. “Major investment has taken our manufacturing capabilities from 800,000 to 3 million IOLs per year, and prepares us for the US launch of the »RayOne Aspheric fully preloaded IOL injection system in 2018.”